Does duration of caffeine therapy in preterm infants born ≤1250 g at birth influence neurodevelopmental (ND) outcomes at 3 years of age?

A Lodha; Y Rabi; A Soraisham; J Dobry; Arijit Lodha; H Amin; E Al Awad; A Sahai; V Bhandari

doi:10.1038/s41372-018-0106-y

Back

Does duration of caffeine therapy in preterm infants born ≤1250 g at birth influence neurodevelopmental (ND) outcomes at 3 years of age?

Journal article

Open access

Peer reviewed

Does duration of caffeine therapy in preterm infants born ≤1250 g at birth influence neurodevelopmental (ND) outcomes at 3 years of age?

A Lodha, Y Rabi, A Soraisham, J Dobry, Arijit Lodha, H Amin, E Al Awad, A Sahai and V Bhandari

Journal of perinatology, v 38(7), pp 889-899

Jul 2018

DOI: https://doi.org/10.1038/s41372-018-0106-y

PMID: 29740190

Featured in Collection : UN Sustainable Development Goals @ Drexel

Files and links (1)

url

https://doi.org/10.1038/s41372-018-0106-yView

Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze), Open

Abstract

To evaluate the effect of duration of caffeine use on long-term neurodevelopmental (ND) outcomes at 3 years corrected age (CA) in preterm infants with birthweights (BW) ≤ 1250 g. All surviving infants with BW ≤ 1250 g admitted to the Foothills Medical Center neonatal intensive care unit (NICU) from January 2002 to December 2009 who received the first dose of caffeine in the first week of life and were followed up at three years CA were included in the study. Demographics and follow-up outcomes were compared based on early cessation of caffeine ≤ 14 days (ECC), intermediate cessation of caffeine 15-30 days (ICC), and late cessation of caffeine >30 days (LCC). The primary outcome of ND impairment was present if a child had any one of the following: cerebral palsy, cognitive delay, visual impairment, or hearing impairment or deafness. Univariate and logistic regression analyses were performed. Of the 508 eligible infants, 448 (88%) were seen at 3 years CA at follow-up. ECC (n = 139), ICC (n = 122) and LCC (n = 187) groups had a median (range) BW of 979 (560-1250), 1010 (530-1250), and 980 (520-1250) g (p = 0.524) and median (range) gestational age (GA) of 27 (23-33), 28 (24-33), and 27 (24-32) weeks, respectively (p = 0.034). In logistic regression models adjusting for GA, maternal smoking, and each neonatal risk factor separately (IVH, NEC, sepsis, blood transfusions, BPD, postnatal dexamethasone, SNAP-II, and ventilator days), none of the models showed a statistically significant association between caffeine duration and ND impairment. The duration of caffeine use in premature infants in the NICU does not impact on long-term ND outcomes at 3 years CA.

Metrics

8 Record Views

6 citations in Web of Science

6 citations in Scopus

Details

Title: Does duration of caffeine therapy in preterm infants born ≤1250 g at birth influence neurodevelopmental (ND) outcomes at 3 years of age?
Creators: A Lodha - University of Calgary
Y Rabi - University of Calgary
A Soraisham - University of Calgary
J Dobry - University of Calgary
Arijit Lodha - University of Calgary
H Amin - Alberta Children's Hospital
E Al Awad - Alberta Health Services, Calgary, AB, Canada
A Sahai - University of Calgary
V Bhandari - Drexel University
Publication Details: Journal of perinatology, v 38(7), pp 889-899
Publisher: Springer Nature
Resource Type: Journal article
Language: English
Academic Unit: Pediatrics
Web of Science ID: WOS:000440337800019
Scopus ID: 2-s2.0-85046633740
Other Identifier: 991019167815304721

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Domestic collaboration; International collaboration
Web of Science research areas: Obstetrics & Gynecology; Pediatrics